Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587040 · ClinicalTrials.gov registry record · Phase 1
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01587040 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 61 participants.
The verdict
NCT01587040, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from treatment.
Interventions
- DRUG SAR245409
- DRUG SAR245408
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-07-20 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587040
The ClinicalTrials.gov registry entry for NCT01587040 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAR245409 is the first listed.
NCT01587040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01587040 about?
NCT01587040 is a clinical study titled "Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen". Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from treatment.
What is the current status of trial NCT01587040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2012-07-20. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT01587040?
The interventions under investigation include: SAR245409 (DRUG), SAR245408 (DRUG).
Who is sponsoring clinical trial NCT01587040?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.